{"name":"Calluna Pharma AS","slug":"calluna-pharma-as","ticker":"","exchange":"","domain":"callunapharmaas.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CAL101","genericName":"CAL101","slug":"cal101","indication":"B-cell malignancies (in development)","status":"phase_2"}]}],"pipeline":[{"name":"CAL101","genericName":"CAL101","slug":"cal101","phase":"phase_2","mechanism":"CAL101 is a phosphatidylinositol 3-kinase (PI3K) delta inhibitor that selectively blocks PI3K signaling in immune cells to modulate immune responses.","indications":["B-cell malignancies (in development)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNSnpfRV9EVjZrMHRTa0dSS28yb3cwblU1bmlGLVlnWWRaaWxWN2hwVVZhc1hGWDY1N0dBSHpVSW1oQ0NtWUlRa0Y2enptZEdpSG9FQXRWc1Z6eEI4TEh5OUhmbG1YUGVfOWljanoxOGRwbGNkM1M2VzB3cldvOXB6d0FYaHlETlhIcFl4dWNjTjZ3M3EwZDkwVjFfd1pTV0NPUTNFN0kwN3R0d0wxUkZWZkZYMEItQ090LXJLQ1BXNXlxYzVUOWFNSmRyNG00emYyOEhhYUMwM3E3Snp4ZkREeFpYTTk?oc=5","date":"2025-12-15","type":"pipeline","source":"Business Wire","summary":"Calluna Pharma Announces the Appointment of Gijs van den Brink, MD, PhD, as Independent Director - Business Wire","headline":"Calluna Pharma Announces the Appointment of Gijs van den Brink, MD, PhD, as Independent Director","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxOaDRoc0I2VGVsNEJnYkp5djlUYUxSRV9Pa1R1anQ4a1lPNmVRRF9jWlZWRXQtclJtSXhpR1EzNjdDeW9hczhhdFZVU0U2Q1ZMZWxTcnBQTzdySGdPdFJVQnNPSk9tdFJMemZGdk1LV3RnU0pqeC03a2FYc1Vma0V2TmpXaFpyangwQXJsTEFmS2tMSEZndV9oT3FnNTFCeWthV2loUUxkcW43RGRFSHVwQS1wOHd1WHRhVjJmWXk1OFJlR3pTUHM3SkF4dU03NjdyM1Q4d3FjMHJrQXhuYWxOVnBVQ2pST0dBLTlIZi1Mem5lUndJbWY0dmRuVmU2dnJHNGE1NzV2OFJYVFZyMktaa01KSTJUdw?oc=5","date":"2025-10-31","type":"regulatory","source":"Business Wire","summary":"Calluna Pharma Announces U.S. FDA Orphan Drug Designation Granted to CAL101 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) - Business Wire","headline":"Calluna Pharma Announces U.S. FDA Orphan Drug Designation Granted to CAL101 for the Treatment of Idiopathic Pulmonary Fi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQRzlUNlh2TG1KVFdOMWMtNTNvSVE5dlc5M0huU1FWVm9ucDRsRmJNTWZVRmhueGlDTFZNbkRyMnlRR1BiNHdrVVJHbFMwaXA4R3dwNlpSU3RKckp0UllVdjh4aDJvTEJ1ZnBsLW1iRUtWaDROX2taRGc3QkVMSlBlV3VKLVhqU3haM2xMODdNbWpqUTM3am5VSmxFMWstbU1BZ0NPaWs1RFFlTGpwdUNRQ3BoR1VQbTFSVzJVMVB4OHVHblZKNC1uOU5feERDcmFRdTQ4c2pB?oc=5","date":"2025-09-02","type":"trial","source":"Managed Healthcare Executive","summary":"Calluna Pharma Launches Phase 2 AURORA Trial of CAL101 to Halt Lung Decline in IPF Patients - Managed Healthcare Executive","headline":"Calluna Pharma Launches Phase 2 AURORA Trial of CAL101 to Halt Lung Decline in IPF Patients","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxQMm9zckV6VVBzenhUNUxmeUpZbzMtZVh4TGxaUUJyaUFVUUZDem5ZczJaRGRwVzdsU1NIUWpqMHhvVVNXTmxwNE9zT3EtRk53aThPcFVwZG5hODRHOE1rcHB1ODZEWjhfNEZKMGRlblU1NWtnYzk2bk5LMmE4R3d5Nnl4NjhQWXM0N00tMXhYMTU5NHppUzk4OXNqVzZXdldCYWdyQXR5Nk81aDlaVDVKVUtDdXFJR2dITGIzYXpXSGZkQW5Vak1fUXRvUVB5ZTI4bWdBZ2lIekNoa1NPTHRfSmQ0RVFuUTBxYkVnN2hSLU11SGV5ejRQRWZQRVZwV1pIU3g2SkQwbVo?oc=5","date":"2025-08-27","type":"trial","source":"News-Medical","summary":"Qureight's AI 3D imaging platform to support Calluna Pharma's Phase 2 AURORA study of CAL101 in idiopathic pulmonary fibrosis (IPF) - News-Medical","headline":"Qureight's AI 3D imaging platform to support Calluna Pharma's Phase 2 AURORA study of CAL101 in idiopathic pulmonary fib","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQaWtuRVZsU1pFc0I2ck5JU3BXenlpamM0ZHJEMWJIUXhqdXBHZ21PTjRRcmxySWlJRDF0VzRTY09GME5LUjVoWkwyVzV2Mm9yRXZoTGYxeXNhM0xYWWxLdzhBRV9EUWpWNmgycjlNaldhZF9ib3R1Zzh4cG8xbV83MjV5emNEWUhtZ3JvV3ZVUUxtMVdYVlVVUmdFazNWOXo2Nmk3U1JfTTlzbXR1?oc=5","date":"2025-08-26","type":"pipeline","source":"European Biotechnology Magazine","summary":"Calluna Pharma starts efficacy test with unique IPF antibody - European Biotechnology Magazine","headline":"Calluna Pharma starts efficacy test with unique IPF antibody","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxONDVqYkNBREhPY2RVeEV6a3NidlhKUnV0TWczeHZ5RmN2RzFjajJqc3FWc2FGYTFqRzlJMDlvMXZxekRsZTVjNFhUNDZIck9tN1lKdGk5TXhoLTVJdU9RV2pBbHhhZTd5OTNHTVVmdzdDSkdsOUkxcWY0MFhxRmZwOGk0SnFqM25qODFFWUpSVnpGbktKT0RMaUtnOGdHUDRYeWI0TmVPajhwVlJ0VHRZODc2QmZPbnpOUVM3NGwwQkVOai1Mb0JoU3M3SF9fVWdBRnNiMkQ5bmNKMFBYRWxPdkFoNzB5TzN4MVBXdzRzc2Z4UQ?oc=5","date":"2025-08-25","type":"trial","source":"Business Wire","summary":"Calluna Pharma Announces Initiation of Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis - Business Wire","headline":"Calluna Pharma Announces Initiation of Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNTC1ENkVrQk1oek5qWVZ4OEVJbU9qcmlHR2w3bVNfQmxhX3pJV2xyYlMxY21JUWZILWw5d0djYjRWNWwyblJ2SENIcDhVQ2M3elBscFZfQ2hLcFN6dklFQnhpZ05tVFItSUk2OUF2N2FBSlJwMVVwQ2F4NWcxRWVkbk90NVFwb3M?oc=5","date":"2024-10-24","type":"trial","source":"Clinical Trials Arena","summary":"Calluna completes CAL101 Phase I clinical study for fibrotic conditions - Clinical Trials Arena","headline":"Calluna completes CAL101 Phase I clinical study for fibrotic conditions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9GU3Mya294RXRDc3ZOdW1vWnpYVHVfOU53amc1VnVQVTVYV0gtN3dmYVFqcGF5STQ4RVBIcV83MWVFSHp2UTVaNTFTaWNxR2FQZHpDUndEVFRTQ19VX2psSGZSZWFXRmk3aUR0UWlTTmk0aGk3eGE3a1p3?oc=5","date":"2024-10-09","type":"pipeline","source":"Contract Pharma","summary":"Calluna Pharma Names CEO - Contract Pharma","headline":"Calluna Pharma Names CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxQLWZBMktTdXUxWThpMU52bGw2Wlc2cXY5VTBqb1F1M3dPazVqLS04dGdKcl9OVGtHS01QTE9TR2pXSC0tZWVVQXR2eWN2LTJMWi11U0xJN2dHYnhJN044MVYtZ29RVE9FUHRJX1F2ZEVNMUFTdlNpWHZJZ0VkNk9PMHMySG93UTdERU9pVldGVkZyLWtrdXdGbW9qVENKNEJiQ3YwYXVfRVRPODd3MVgwYTJ1T1VrRWpxeVFPLVlJcER4Q00yV3BTaEJrTUpxSlJUNFZhYThlTmU4WXB5alVXN1EyZHZpVU5qUWdF?oc=5","date":"2024-08-07","type":"pipeline","source":"respiratory-therapy.com","summary":"Calluna Pharma Launches with €75M for Inflammatory and Fibrotic Disease Therapies - respiratory-therapy.com","headline":"Calluna Pharma Launches with €75M for Inflammatory and Fibrotic Disease Therapies - respiratory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOQ29VeDFZR0hqaXp5QnlmRHpkdERkY1ZnVzdaYXFzb2xsc0cwbVNrUi1mR0RPS0l3Wkx0S3JDS1p4Q192MEc0LUc0LXEwa2J2TjByUTY1Y3dMbkhHY3dpaktZS3FtZ3FvRTZtOGdUTWZNWnlrTDdCWVNkWUVKdUZFT3BENGhrblFwcDVuOW1aazFDaHpLWmtCVENqZHZCNjBNZzJLTkpiSUJIQnF0SWwxaXlHRm9iUU9wMUFJ?oc=5","date":"2024-02-02","type":"pipeline","source":"BioWorld News","summary":"Born of Oxitope and Arxx, Calluna emerges with €75M series A for immunology push - BioWorld News","headline":"Born of Oxitope and Arxx, Calluna emerges with €75M series A for immunology push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOOW9SUEo0WnViZVJZeWx4RDV2WHFDUUFDVFhtOVZoMUs1cTMySHB1T2JpT01VRUh1TVNIVTlIMklWUnBaYndNajlwM25qOFdVbnk4djlJbzFFT2M3YVllbnBSeEhPZFhzT1NJdTAwaXhkTFZscmpqU3REUFBSdHVrOHg1VExaRFZUMkZEV3Y4LXZaNWstc0Y4M1dXcWswVnkyVVNlTzd4a18?oc=5","date":"2024-01-24","type":"pipeline","source":"PharmaTimes","summary":"Calluna Pharma announces €75m series A financing for immunological diseases - PharmaTimes","headline":"Calluna Pharma announces €75m series A financing for immunological diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOSVIxQ2pQekV5RjRKMVdtVkJtRFYwMzZrUUNwSnFmNEVRcVIzRVZXUjBoRlRMZms2cjhteVphVnFoRnJjV0FCLUZwbXI1MmdFQnFnbXROajZiSjBjQXdWaktKb0VpNnJ4Zm95em9BV19QNzdER21qVDZNVndSR3JwajlLemQyVGV5bFZFd0ZvRFpHWnFrWllXT2s3cUszQlVWWmU5YzVyaG1xN185eFBQNDdEX0c3YUNGUGFiYUhn?oc=5","date":"2024-01-23","type":"pipeline","source":"Pharmaceutical Technology","summary":"Newly launched Calluna raises $81m to advance monoclonal antibody pipeline - Pharmaceutical Technology","headline":"Newly launched Calluna raises $81m to advance monoclonal antibody pipeline","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}